About: Development of a model care pathway for the management of Hymenoptera venom allergy: evidence-based key interventions and indicators

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Development of a model care pathway for the management of Hymenoptera venom allergy: evidence-based key interventions and indicators Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Development of a model care pathway for the management of Hymenoptera venom allergy: evidence-based key interventions and indicators
Creator	Novembre, Elio Bonadonna, Patrizia Bilò, Maria Mauro, Marina Pravettoni, Valerio Bignardi, Donatella Corsi, Alice Micheletti, Rebecca Papa, Roberto Quercia, Oliviero
source	PMC
abstract	BACKGROUND: Hymenoptera venom allergy (HVA) is an underestimated condition representing an important cause of morbidity and mortality worldwide. Preventing future allergic reactions in patients who have already developed a systemic reaction is based on the correct management of the acute phase of the reaction followed by a correct diagnosis and, where indicated, prescription of adrenaline autoinjectors and VIT. A possible strategy to optimize care processes and to improve outcomes is the implementation of a Diagnostic and Therapeutic Care Pathways, also known as Integrated Care Pathways or Clinical Pathways (CPWs). The aim of the care pathway is to enhance the quality of care by improving risk‐adjusted patient outcomes, promoting patient safety, increasing patient satisfaction, and optimizing the use of resources. To our knowledge, currently in Italy as well as in Europe, there is no CPWs codified for the management of HVA patients. This paper describes the development of the clinical content of a care pathway for the management of HVA. METHODS: The methodology applied is based on the eight step method to build the clinical content of an evidence-based care pathway suggested by Lodewijckx et al. RESULTS: Three hundred and seventeen different clinical activities were extracted from the selected literature. The expert panel was involved in their evaluation, expressing a judgment of relevance through the Delphi study. As a result, 126 clinical activities were appraised to be valid and feasible. The final recommendations (126) were translated into 123 key interventions. Six indicators were produced by the clinical activities. CONCLUSION: A set of 123 key interventions and of six process indicators were found to be appropriate for the development and standardization of the clinical content of the Hymenoptera venom allergy care pathway.
has issue date	2020-03-04(xsd:dateTime)
bibo:doi	10.1186/s13601-020-00312-3
bibo:pmid	32158533
has license	cc-by
sha1sum (hex)	188b1ecf98fbd20b23fab6140760d976a5ab120b
schema:url	https://doi.org/10.1186/s13601-020-00312-3
resource representing a document's title	Development of a model care pathway for the management of Hymenoptera venom allergy: evidence-based key interventions and indicators
has PubMed Central identifier	PMC7055031
has PubMed identifier	32158533
schema:publication	Clin Transl Allergy
resource representing a document's body	covid:188b1ecf98fbd20b23fab6140760d976a5ab120b#body_text
is schema:about of	named entity 'care' named entity 'Diagnostic' named entity 'worldwide' named entity 'venom' named entity 'ADJUSTED' named entity 'STRATEGY' named entity 'SYSTEMIC REACTION' named entity 'PRESCRIPTION OF' named entity 'PATIENT SAFETY' named entity 'WHERE' named entity 'PATIENTS' named entity 'USE OF' named entity 'PREVENTING' named entity 'care pathway' named entity 'phase' named entity 'patients' named entity 'adrenaline' named entity 'mortality' named entity 'allergy' named entity 'patient' named entity 'care pathway' named entity 'codified' named entity 'reaction' named entity 'model' named entity 'HVA' named entity 'venom' named entity 'patient satisfaction' named entity 'allergy' named entity 'patient outcomes' named entity 'evidence-based' named entity 'venom' named entity 'developed' named entity 'venom' named entity 'false negative' named entity 'allergy' named entity 'cutaneous' named entity 'vascular diseases' named entity 'cutaneous' named entity 'health care' named entity 'ACE-inhibitors' named entity 'levocetirizine' named entity 'immunotherapy' named entity 'venom' named entity 'cardiovascular' named entity 'emergency room' named entity 'anaphylaxis' named entity 'Delphi method' named entity 'anaphylaxis' named entity 'clinical care' named entity 'feasible set' named entity 'anaphylaxis' named entity 'Delphi' named entity 'Italy' named entity 'evidence-based medicine' named entity 'IgE' named entity 'Medline' named entity 'insect' named entity 'allergy' named entity 'clinical history' named entity 'systemic reactions' named entity 'HVA' named entity 'venom' named entity 'Italian Federation' named entity 'evidence-based' named entity 'IgE' named entity 'biphasic' named entity 'evidence-based' named entity 'HVA' named entity 'Emergency Department' named entity 'clinical pathway' named entity 'quality of life' named entity 'epidemiologically'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software